Disease · MONDO_0044915

salivary duct carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. salivary duct carcinoma. Diseases, record MONDO_0044915. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0044915

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: salivary duct carcinoma; Open Targets
Open Targets ID: MONDO_0044915; Open Targets
Other names: carcinoma of duct of salivary gland, carcinoma of salivary duct, carcinoma of the salivary duct, duct of salivary gland carcinoma, high grade salivary duct carcinoma; Open Targets
NCI Thesaurus: C5904; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 20 of its 20 drugs, from ClinicalTrials.gov; Open Targets

Drugs20

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BICALUTAMIDE	CHEMBL409	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ABIRATERONE ACETATE	CHEMBL271227	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DUTASTERIDE	CHEMBL1200969	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
GOSERELIN	CHEMBL1201247	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LEUPROLIDE ACETATE	CHEMBL1200775	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 20

See all 20 drugs

Targets34

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GNRHR	Gonadotropin-releasing hormone receptor	3	Gonadotropin-releasing hormone receptor agonist	Phase 2	https://conductscience.org/library/genes/2798	Drugs and targets
AR	Androgen receptor	2	Androgen Receptor antagonist	Phase 2	https://conductscience.org/library/genes/367	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	1	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
CYP17A1	Steroid 17-alpha-hydroxylase/17,20 lyase	1	Cytochrome P450 17A1 inhibitor	Phase 2	https://conductscience.org/library/genes/1586	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	1	Receptor protein-tyrosine kinase erbB-2 inhibitor	Phase 2	https://conductscience.org/library/genes/2064	Drugs and targets
FOLH1	Glutamate carboxypeptidase 2	1	Glutamate carboxypeptidase II binding agent	Phase 2	https://conductscience.org/library/genes/2346	Drugs and targets
KDR	Vascular endothelial growth factor receptor 2	1	Vascular endothelial growth factor receptor 2 inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
MET	Hepatocyte growth factor receptor	1	Hepatocyte growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/4233	Drugs and targets
PDCD1	Programmed cell death protein 1	1	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets

1 to 10 of 34

See all 34 targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03172624	Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer	Phase 2	64	2025-12-18	Salivary Gland Cancer	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT01969578	Androgen Deprivation Therapy in Advanced Salivary Gland Cancer	Phase 2	149		Salivary Gland Cancer	BICALUTAMIDE, CARBOPLATIN, CISPLATIN, DOXORUBICIN, PACLITAXEL, TRIPTORELIN	Its record names the disease	ClinicalTrials.gov
NCT03614364	Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma	Phase 2	41		Salivary Duct Carcinoma	TRASTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT06348264	Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma	Phase 2	37		Salivary Gland Neoplasm Duct	LEUPROLIDE ACETATE, REZVILUTAMIDE	Its record names the disease	ClinicalTrials.gov
NCT05513365	Phase II Dutasteride in Combination With CAB vs CAB in SDC	Phase 2	26		Salivary Duct Carcinoma	BICALUTAMIDE, DUTASTERIDE, GOSERELIN	Its record names the disease	ClinicalTrials.gov
NCT03729297	Cabozantinib in Advanced Salivary Gland Cancer Patients	Phase 2	25		Salivary Gland Cancer	CABOZANTINIB	Its record names the disease	ClinicalTrials.gov
NCT02867852	Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers	Phase 2	24		Salivary Glands Tumors	ABIRATERONE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT00984217	Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies	Phase 2	0		Adenoma, Pleomorphic, Mixed Salivary Gland Tumor, Salivary Gland Tumor, Mixed, Syringoma, Chondroid	PANITUMUMAB	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
R/M Adenoid Cystic Carcinoma (ACC) vs R/M SGC of Any Histology, Except ACC (Non ACC): deaths from any cause	6 of 32	7 of 32	64	NCT03172624	Trial comparisons
R/M Adenoid Cystic Carcinoma (ACC) vs R/M SGC of Any Histology, Except ACC (Non ACC): serious adverse events	18 of 32	9 of 32	64	NCT03172624	Trial comparisons

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37939426	DERIVED	1	PubMed
37620627	DERIVED	1	PubMed
34920917	DERIVED	1	PubMed
34597119	DERIVED	1	PubMed
34503735	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0044915

GET https://conductscience.org/api/diseases/v1/MONDO_0044915/targets?page=2

API reference For AI assistants